Price
No data yet.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.78T | $203.33B | $63.91 |
| 2024 | $4.58T | $107.93B | $34.17 |
| 2023 | $4.26T | $144.07B | $46.05 |
| 2022 | $4.03T | $317.02B | $102.15 |
| 2021 | $3.57T | $230.06B | $73.57 |
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $0.14 per share
Typical surprise -85.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.23 vs $0.17beat
- Wed, May 13$-0.05 vs $0.21miss
- Thu, Jan 29$0.21 vs $0.55miss
- Thu, Oct 30$-0.02 vs $0.44miss
- Wed, Jul 30$0.52 vs $0.47beat
- Thu, May 8$-0.22 vs $0.24miss
Estimates and results for TAK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TAK officers and directors.
- Bought
- —
- Sold
- $9.7m
0 trades
16 trades
- Shannon Elaine Marysold
- Farajallah Awny Samaan Botrossold
- Ibrahim Ramy Riad Ahmedsold
- Pacheco Rhonda Janicesold
- Duprey Lauren Rusckowskisold
- Plump Andrew Stewartsold
- Pignagnoli Agosti Marcellosold
- Bitetti Teresa Mariesold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from TAK's reported EPS growth of -3.5% a year over 4 years.
- EPS in 5 years
- $54.01
- Implied price
- $2,485
- Return from $17.39
- 169.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1,235 — today's price is already 98.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 32 | 39 | 46 | 53 | 60 |
|---|---|---|---|---|---|
| -13.5% | 124.9% | 134.0% | 141.8% | 148.8% | 155.0% |
| -8.5% | 137.9% | 147.5% | 155.8% | 163.1% | 169.8% |
| -3.5% | 150.9% | 161.0% | 169.8% | 177.5% | 184.5% |
| 1.5% | 163.9% | 174.5% | 183.8% | 191.9% | 199.2% |
| 6.5% | 176.9% | 188.1% | 197.7% | 206.3% | 214.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newszacks.com·5h ago·Positive
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
View source ↗